Rigi10™ Malleable Penile Prosthesis
Erectile Dysfunction
ApprovedCommercial
Key Facts
About Rigicon
Rigicon is a privately held medical device company specializing in prosthetic urology, with a core focus on erectile dysfunction (ED) treatment. The company's primary commercial product is the Rigi10™, a next-generation malleable penile prosthesis featuring proprietary technologies like HydroShield™ coating and Flexible Rod Technology™. Rigicon operates globally from its headquarters in Ronkonkoma, New York, and positions itself as a scientific partner aiming to change the practice of prosthetic urology through innovation and a complete product portfolio. The company is in a revenue-generating, commercial stage, serving the urology surgical market.
View full company profileTherapeutic Areas
Other Erectile Dysfunction Drugs
| Drug | Company | Phase |
|---|---|---|
| CF602 | Can Fite Biopharma | Preclinical |
| E300 ESWT System | Wikkon | Commercial |
| Sildenafil Citrate | Azico Biophore | Commercial |
| Sildenafil Formulation | InnovaZone Labs | Approved |
| UNITED Study (Investigational Inflatable Penile Prosthesis) | Rigicon | Clinical Investigation |
| ASP-001 | Aspargo Laboratories | Approved |
| Sildenafil-loaded Z-pods® | Atticus Pharma | Pre-clinical |
| FGF-based Therapeutic | Venturis Therapeutics | Pre-clinical |
| TPN171 (Simenafil hydrochloride) Tablets | Vigonvita | Approved |
| DehydraTECH-sildenafil | Lexaria Bioscience | Human Clinical |